RxDoctor Payments Data

Lila Orr

Dermatology · Englewood, CONPI 1841223526

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,050 of the $7,313 with a category attached, or 69.1%. Galderma Laboratories, L.p. accounts for 72.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $5,531 and has fallen 91.9% since, to $449 in 2025.

$7,313in general payments, 2019–2025

Across 104 payments — averaging $70.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$5K
  • AbbVie$1K
  • Pfizer$200
  • Incyte Corporation$120
  • E.r. Squibb & Sons, L.L.C.$74
  • Sun Pharmaceutical Industries Inc.$60
  • plus $187 from 5 others

What the payments were for

  • Speaking & faculty fees$5,05069%
  • Travel & lodging$841%
  • Food & beverage$2,16430%
  • Education$150%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,313 in reported general payments places this provider in the 80th percentile of 280 dermatology providers in Colorado.

See all dermatology providers in Colorado

Medicare billing

Part B allowed, 2024
$114,358
Medicare patients
490
Services billed
2,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib23$156,947
Dupixent PenDupilumab15$57,921
Clobetasol Propionate44$2,312
Fluorouracil15$1,436
ValacyclovirValacyclovir Hcl42$894
Doxycycline Hyclate26$589
Ketoconazole48$584
Spironolactone30$506
Triamcinolone Acetonide32$354
Clindamycin Phosphate12$326
Hydroxychloroquine Sulfate13$294
Minoxidil22$156
Cephalexin11$65
Prednisone11$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,361$156,94723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 280 dermatology providers in Colorado.

Other dermatology in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →